FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Parker Katherine 		2. Issuer Name and Ticker or Trading Symbol

ENDOCYTE INC [ ECYT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
VP of Human Resources
(Last)          (First)          (Middle)

3000 KENT AVE, SUITE A1-100 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/5/2018
(Street)

WEST LAFAYETTE, IN 47906
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

10/9/2018 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   10/5/2018     S    6771   (1) D $15.5540   70869   (2) D    
Common Stock                  1200   I   By trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Represents the sale of 6,771 shares in multiple transactions ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5540. The 6,771 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 15,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
(2)  Includes 520 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on the Form 4 filed by the reporting person on October 9, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Parker Katherine
3000 KENT AVE, SUITE A1-100
WEST LAFAYETTE, IN 47906

VP of Human Resources

Signatures
/s/ Beth A. Taylor, Attorney-in-fact for Katherine Parker (power of attorney previously filed) 10/16/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Endocyte, Inc. (delisted) Charts.
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Endocyte, Inc. (delisted) Charts.